Incyte Gets CRL for Zynyz in Metastatic Lung Cancer

Incyte Corporation disclosed in a SEC filing dated March 6, 2026, that the US Food and Drug Administration issued a Complete Response Letter on February 27, 2026, for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection (375 mg). The sBLA sought approval for the treatment of adult patients with metastatic non-small cell lung cancer in combination with platinum-based chemotherapy. The application was supported by data from the Phase 3 POD1UM-304 trial, results of which were announced in December 2024.

The CRL cited inspection findings at Catalent Indiana, LLC, a third-party fill-finish facility now part of Novo Nordisk, as the sole approvability issue. The FDA did not raise concerns regarding the efficacy or safety data supporting Zynyz in NSCLC, nor did it cite issues with the third-party drug substance manufacturer. The inspection findings at Catalent Indiana were not specific to Zynyz, indicating the manufacturing compliance matter extends beyond this particular product. Practically, the CRL means Incyte cannot receive approval for this indication until the facility-related issues are resolved to FDA's satisfaction.

Retifanlimab-dlwr is a humanized monoclonal antibody that binds to programmed death receptor-1, blocking its interaction with PD-L1 and PD-L2. This mechanism reactivates T-cell-mediated anti-tumor immune responses. Metastatic NSCLC remains one of the leading causes of cancer-related mortality, and PD-1 checkpoint inhibitors combined with platinum-based chemotherapy have become a standard first-line treatment approach. Several PD-1 and PD-L1 inhibitors, including pembrolizumab and nivolumab, are already approved in this setting. Retifanlimab's entry would have added another option in a competitive but clinically relevant space.

Retifanlimab originated at MacroGenics, Inc., where it was designated MGA012. In November 2017, Incyte entered a global collaboration and license agreement with MacroGenics, obtaining exclusive worldwide development and commercialization rights. MacroGenics received a $150 million upfront payment with eligibility for up to $760 million in additional milestones plus tiered royalties. Since that agreement, Incyte has held sole responsibility for regulatory strategy, clinical development, and commercialization.

Zynyz received FDA accelerated approval in March 2023 for metastatic or recurrent locally advanced Merkel cell carcinoma, establishing its initial US market presence. The NSCLC sBLA represented Incyte's effort to expand the label into a larger oncology population. The provided materials do not reference prior CRLs for this specific sBLA or for the original Merkel cell carcinoma BLA. No information was available regarding approvals of retifanlimab in other regulatory jurisdictions such as the EU or Japan.

The NSCLC treatment landscape includes multiple approved checkpoint inhibitor combinations. AstraZeneca's tremelimumab received FDA approval in November 2022 in combination with durvalumab and platinum-based chemotherapy for metastatic NSCLC. Targeted therapies addressing specific mutations, such as amivantamab for EGFR exon 20 insertions and sotorasib and adagrasib for KRAS G12C mutations, have also received approvals in recent years. Retifanlimab's pursuit of the broader first-line metastatic NSCLC population places it in direct competition with established PD-1 and PD-L1 agents rather than mutation-specific therapies.

Incyte stated it is working with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission. The resolution timeline depends on Catalent Indiana's ability to remediate the inspection findings and satisfy FDA requirements, a process over which Incyte has limited direct control. The company did not disclose a projected resubmission date or indicate whether alternative manufacturing arrangements are under consideration.

Spot something wrong? Report an issue with this article

The AllSci Brief